The Discounted Cash Flow (DCF) valuation of Sigilon Therapeutics, Inc. (SGTX) is (454.60) USD. With the latest stock price at 22.47 USD, the upside of Sigilon Therapeutics, Inc. based on DCF is -2123.2%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.4% - 8.4% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (1,104.31) - (291.11) | (454.60) |
| Upside | -5014.6% - -1395.5% | -2123.2% |